Women in Oncology: Career Obstacles Turned Into Opportunities
July 11th 2022Judith Karp, MD; Azra Raza, MD; and Michelle M. Le Beau, PhD, share the challenges they chose to mold into career goals, including developing a new technology to study cell cytokinetics, identifying gene phenotypes, and recognizing that leukemia diseases stem from the same root issues in DNA.
Women in Oncology: How Leukemia Treatment has Changed and Stayed Stagnant Over the Years
July 8th 2022Judith Karp, MD; Azra Raza, MD; and Michelle M. Le Beau, PhD, highlight the decades-long evolution of the leukemia field and express challenges such as defining the causes of leukemia and developing therapies to treat the disease and mitigate adverse effects like bone pain.
Preview of ASCO 2022: Dr Everett Vokes
June 5th 2022OncLive® will be LIVE with OncLive® News Network: On Location at the 2022 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.
Neoadjuvant, Adjuvant Immunotherapies Poised to Revolutionize Outcomes in Resectable NSCLC
Surgical resection remains the key treatment modality for early-stage non–small cell lung cancer; however, both systemic adjuvant and neoadjuvant therapeutics are options that have value for patients.
GI Armamentarium Undergoes Changes With New Treatment Mechanisms and Applications
January 12th 2022Chih-Yi (Andy) Liao, MD, discusses the focus of each presentation at the webinar, which centered on optimizing therapy in advanced pancreatic cancer, the contemporary use of surgery and systemic therapy in NETs, multidisciplinary approaches to hepatocellular carcinoma, and the evolving role of liver transplant and systemic therapy.
Dr. Garassino on the Clinical Implications of Tepotinib in METex14-Altered NSCLC
September 24th 2021Marina Chiara Garassino, MD, professor of Medicine, Hematology and Oncology, The University of Chicago Department of Medicine, discusses the clinical implications of the phase 2 VISION trial evaluating patients with MET exon 14 skipping mutation–positive non–small cell lung cancer.
Early Relapse Confers Worse Prognosis After Transplant, Calling for Novel Options in High-Risk MCL
June 23rd 2021Peter Riedell, MD, discusses the rationale for a study in mantle cell lymphoma, the clinical implications of the findings, and unanswered questions that future research efforts should aim to answer.
Garassino Highlights What’s In Store for Lung Cancer
June 21st 2021Patients with lung cancer were identified as an at-risk group for developing severe complications as a result of SARS-CoV-2 infection, and thoracic oncologists were fast to respond with the establishment of the Thoracic Cancers International COVID-19 Collaboration.